People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Other Health Care, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RESTOR3D, Inc. | — | Other Health Care | Series C | $239.2M | $522.0M | 2020 |
| Deep Blue Medical Advances, Inc. | — | Biotechnology | Series A | $18.1M | $15.5M | 2017 |
| Sparta Biomedical Inc. | — | Other Health Care | Series A | $5.3M | $63.7M | 2021 |
| Reselute, Inc. | — | Other | Seed | $5.1M | $5.3M | 2023 |
Ken Gall at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ken Gall on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cambre Kelly | 2 | 2 |
| Andrew Miller | 1 | 8 |
| Kenneth Gall | 1 | 5 |
| Kurt Jacobus | 1 | 5 |
| Douglas Kohrs | 1 | 4 |
| William Perry | 1 | 3 |
| Michael Porter | 1 | 3 |
| Dimitrios Angelis | 1 | 3 |
| JAMES STUBBS | 1 | 3 |
| ANDREW SUMMERS | 1 | 3 |
| Michael Bates | 1 | 3 |
| Robert Bonczek | 1 | 3 |
| Brian Garvey | 1 | 2 |
| William Rhoda | 1 | 2 |
| Robert Isaacs | 1 | 2 |
| Sean Fontenot | 1 | 2 |
| Neil Meyer | 1 | 2 |
| Brent Duncan | 1 | 2 |
| Michael Fillion | 1 | 1 |
| Stuart Huston | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.